OCT’s comprehensive CRO services portfolio includes over 300 clinical trials in Phases I-IV in 29 therapeutic areas.
Request a Proposal
The OCT team has been managing clinical trials since 2005. We are actively leading projects in Europe and CIS countries, and providing support to our clients from the research planning stage up to drug registration.
Since 2005, OCT has been involved in more than 300 full-service projects and individual clinical development services. Such vast experience allows us to assess potential risks and be able to prevent them at the first stage of project planning.
Therapeutic Expertise in Clinical Study Management
We are proud to offer expertise in a number of therapeutic areas as a mid-size CRO. Cardiology, oncology, infectious disease, and gastroenterology are highlights of ourextensive clinical development portfolio.
OCT Clinical has helped conduct over 65 oncology trials to date, and we are recognized among the top breast cancer CROs for clinical trials in Central and Eastern Europe. With an excellent track record for swift enrollment as well as robust patient engagement solutions, OCT is equipped to meet challenges specific to oncology. CRO services within our scope of expertise also include medical writing, data management, regulatory support, and more.
OCT Clinical has helped conduct a wide range of Phase I-IV infectious disease studies, including three for COVID-19 vaccines and other treatments. With over 15 years of clinical study management expertise, OCT helps advance infectious disease research through a commitment to efficient and high-quality CRO services.
COVID-19 Clinical Trial Expertise:
We are proud to support sponsors working to end the COVID-19 pandemic. Partnering with a qualified CRO for infectious disease trials is the best way to ensure seamless communication as well as timeline and budget adherence. With the demands of the COVID-19 pandemic, OCT Clinical offers sponsors the experience necessary to test their therapies with total compliance and efficiency.
OCT Clinical has helped conduct over a dozen Phase I-IV rheumatology studies. With over 15 years of clinical study management expertise, OCT helps advance rheumatology research through a commitment to efficient and high-quality CRO services .
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
